University of California, Irvine Medical Center

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

Retrieved on: 
Tuesday, October 31, 2023
Genomics, University of California, Irvine Medical Center, Stanford University, CONVERGE, Neuro, Hallucination, Neuroanatomy, Deficit spending, Research, University, Artificial intelligence, Weill Cornell Medicine, Drug discovery, Partnership, DSM-IV codes, Delusion, Cornell University, Patient, Diagnosis, SAN, Pharmaceutical industry, Medical device, Schizophrenia, Biotechnology

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.
  • By combining their respective strengths and resources, Verge Genomics and the Pritzker Consortium aim to make substantial strides in the field of schizophrenia research.
  • "We are thrilled to embark on this transformative journey alongside Verge Genomics, combining their AI-powered CONVERGE platform with the invaluable resources of the Pritzker Neuropsychiatric Disorders Research Consortium.
  • This includes the Pritzker Brain Bank, known for stringent subject selection and comprehensive metadata, coupled with deep expertise in human structural and functional neuroanatomy,” said Richard M. Myers, Ph.D., Co-Project Leader, Pritzker Neuropsychiatric Disorders Research Consortium.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Hereditary Disease Foundation Announces Recipients of Inaugural Transformative Research Award

Retrieved on: 
Wednesday, October 4, 2023
DSM-IV codes, HD, CRISPR, Partnership, Broad Institute, University, Hereditary Disease Foundation, HDF, Therapy, PIAS1, University of California, Irvine Medical Center, Breeding, Gene editing, DRS, MBA, Research, Brain, MIT, AAV, Doctor of Philosophy, Harvard University, Harvard Medical School, Jackson, CAG, Protein, MSH3, Thompson, Transformative research, Mouse, Hospital, Somatic, Massachusetts General Hospital, Gene, Nursing, Medical device, MD

Dr. Davidson’s and Dr. Mouro Pinto’s teams each use cutting-edge methods but take different approaches to advance Huntington’s disease research that, if successful, could lead to truly transformative therapies for Huntington’s disease.

Key Points: 
  • Dr. Davidson’s and Dr. Mouro Pinto’s teams each use cutting-edge methods but take different approaches to advance Huntington’s disease research that, if successful, could lead to truly transformative therapies for Huntington’s disease.
  • The Transformative Research Awards were made possible through a partnership between the Hereditary Disease Foundation and a generous group of anonymous donors.
  • “These new awards are designed to move the most innovative work in Huntington’s disease from concept to practice,” said Meghan Donaldson, CEO of the Hereditary Disease Foundation.
  • “We are funding collaborative research teams who are focused on creating new ways to move toward a disease-modifying treatment and provide transformational new insights to the Huntington’s disease research field.

HerMD Expands Healthcare Team with New Chief Medical Officer Dr. Michael Krychman

Retrieved on: 
Tuesday, October 3, 2023
Lead, Medical Affairs Bureau, University, Passion, Woman, Public key certificate, Cancer, Anne, Supervisor, Chief Medical Officer (Ireland), Menopause, Answer, A Practical Guide to a Spectacular Suicide, AASECT, Knowledge, Mental health service, Health, University of California, Irvine Medical Center, Book, Nursing, Birth control

CINCINNATI, Oct. 3, 2023 /PRNewswire-PRWeb/ -- HerMD, the female-founded physician-led women's health provider committed to revolutionizing women's healthcare strengthens their leadership team with the advancement of Dr. Michael Krychman from Vice President of Medical Affairs and Mental Health Services to Chief Medical Officer.

Key Points: 
  • With this transition as Chief Medical Officer, Dr. Krychman will leverage his expert knowledge and experience to drive HerMD's mission of delivering accessible, comprehensive women's healthcare.
  • "Dr. Krychman has been a trailblazer in women's menopausal and sexual health with a key understanding of both patient and provider experience," says Dr. Somi Javaid, Founder and Lead Chief Medical Officer of HerMD.
  • As Dr. Krychman assumes the role of Chief Medical Officer at HerMD, he will deepen his pivotal role in shaping the organization's strategic direction to bring menopause and sexual healthcare to women through evidence-based treatment options.
  • Founder Dr. Somi Javaid will transition to the role of Lead Chief Medical Officer, continuing to shape the many ways in which HerMD revolutionizes women's health care.

BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint

Retrieved on: 
Monday, September 18, 2023
Toronto Western Hospital, University, Senior, Principal investigator, Bayer, Disease, Cell, Ageing, Hope, PET, COVID, Movement disorder, Șaeș, Transplant, MDS, Parkinson's disease, MD, Patient, Bluerock Wildland Provincial Park, Executive Committee, Seizure, Dyskinesia, Hospital, Principal, S-1 Executive Committee, University of California, Irvine Medical Center, Therapy, Health Canada, International Congress on Tuberculosis, Safety, Pharmaceutical industry, Medical imaging, H1, Research, MISSISSAUGA

Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.

Key Points: 
  • Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.
  • The data was recently presented at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark.
  • There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case.
  • Based on these results, planning is underway for a Phase II study that is expected to begin enrolling patients in H1 (first half) 2024.

Toll Brothers Announces Grand Opening of Resident Amenities at 100 West Community in Anaheim, California

Retrieved on: 
Wednesday, September 13, 2023
Heart, Toll Brothers, University, Student, Downtown Anaheim, Chapman University, California State University, Platinum Triangle, Anaheim, Anaheim GardenWalk, Anaheim Regional Transportation Intermodal Center, Santa Ana River Trail, Santa Ana, Bath, University of California, Irvine Medical Center, Platinum Triangle, NYSE, Hotel

ANAHEIM, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, announced the grand opening of the highly anticipated resident amenities at its 100 West community in Anaheim, California.

Key Points: 
  • ANAHEIM, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, announced the grand opening of the highly anticipated resident amenities at its 100 West community in Anaheim, California.
  • “We invite home buyers to tour our stunning new community amenities and be inspired by the possibilities of living a luxury lifestyle at 100 West,” said Brad Hare, Division President of Toll Brothers in Southern California.
  • The new Toll Brothers model homes are open at the 100 West Sales Center located at 1214 South Urbana Street in Anaheim.
  • For more information on 100 West by Toll Brothers visit 100WestNewHomes.com , or call 866-232-1631.

Alignment Healthcare Welcomes New Chief Medical Officer

Retrieved on: 
Wednesday, September 6, 2023
Linda, University, Internal medicine, Policy, Risk management, CMMI, CMO, Quality, Loma Linda University, Medicare, Center for Medicare and Medicaid Innovation, University of California, Irvine Medical Center, Nursing, Indiana University, Alignment

ORANGE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced the return of Dr. Hyong (Ken) Kim, as its chief medical officer (CMO) effective Sept. 25.

Key Points: 
  • ORANGE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced the return of Dr. Hyong (Ken) Kim, as its chief medical officer (CMO) effective Sept. 25.
  • Dr. Kim played an integral role in Alignment’s founding and, from 2013 to 2018, served as CMO of Alignment Healthcare, where he co-developed, built and managed Alignment’s clinical operations team.
  • “With his intimate knowledge of Alignment, his track record of success and his unique policy perspective, we are confident Ken will help us continue to scale and champion a new path in senior care.”
    Most recently, Dr. Kim served as Chief Clinical Officer at CareConnect MD.
  • Before helping found Alignment, he was one of the clinical leaders at CareMore Health, ultimately serving as CMO from 2009 to 2013.

Heroes in the Fight: Octapharma To Be Honored for Myositis Research at TMA Annual Patient Conference

Retrieved on: 
Wednesday, September 6, 2023
The New England Journal of Medicine, IBM, Hair, Disease, Polymyositis, Interim, Bell, University, DM, Arthralgia, University of California, Irvine Medical Center, Food and Drug Administration, Skin, Progress, Inflammation, MS, Organization, Heroes, Patient, Swelling, Autoimmune disease, Symbiosis, Grammy Awards, Rare, FDA, ALS, Conference, Food, Pulmonary fibrosis, TMA, Pharmaceutical industry, Myositis, Dermatomyositis, Octapharma, MD, Research

PARAMUS, N.J., Sept. 6, 2023 /PRNewswire/ -- Octapharma USA will be presented with the Research & Development Award for Outstanding Innovation in Myositis Research during the Heroes in the Fight Awards Celebration at The Myositis Association's 2023 International Annual Patient Conference to be held September 7 - 10 in San Diego.

Key Points: 
  • "TMA is grateful to Octapharma for being the first pharmaceutical company to take the chance on a treatment for this rare autoimmune disease of the muscles.
  • "We are honored to be recognized by TMA for Octapharma's groundbreaking research on dermatomyositis," said Octapharma USA President Flemming Nielsen.
  • "TMA and Octapharma are celebrating special anniversaries this year, and we congratulate TMA on 30 great years serving the myositis community.
  • Octapharma is the Premier Sponsor for the conference, which features myositis specialists and expert presenters on everything related to these debilitating diseases.

BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint

Retrieved on: 
Monday, August 28, 2023
University, Senior, University of California, Irvine Medical Center, Bayer, Disease, Cell, Ageing, Hope, PET, COVID, Șaeș, Transplant, MDS, Movement, Parkinson's disease, MD, Patient, Bluerock Wildland Provincial Park, UCI School of Biological Sciences, Executive Committee, Seizure, Neurology, Dyskinesia, Principal, S-1 Executive Committee, Therapy, International Congress on Tuberculosis, Safety, Pharmaceutical industry, Medical imaging, H1, Research

Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.

Key Points: 
  • Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.
  • The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.
  • There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case.
  • Based on these results, planning is underway for a Phase II study that is expected to begin enrolling patients in H1 (first half) 2024.

Dr. Andres Betts Joins Pain Medicine Associates - Mission Viejo, California

Retrieved on: 
Tuesday, July 18, 2023
Pain disorder, University, Long Beach, California, Cranial nerves, Critical Care Medicine (journal), Skiing, Sciatica, Alfred Noble Prize, Spine, Radiofrequency ablation, Suite, Piriformis syndrome, PMA, University of California, Irvine Medical Center, Patient, Physician, Pain Clinic, Associate, Mountaineering, Pain, Diagnosis, Sacral fracture, Bone fracture, General surgery, Nursing, Dentistry, Anesthesiology, Medicine

MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice. He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.

Key Points: 
  • MISSION VIEJO, Calif., July 18, 2023 /PRNewswire-PRWeb/ -- Pain Medicine Associates (PMA) is pleased to announce that interventional pain management specialist Andres Betts, M.D., has joined the company's Mission Viejo, California pain management practice.
  • He began seeing patients on July 3rd at the office, located at 26137 La Paz Rd, Suite 140, Mission Viejo, CA 92691.
  • Dr. Betts is an innovative, board-certified, fellowship trained interventional pain management physician that specializes in the diagnosis and treatment of pain disorders.
  • He founded the Pain Clinic in Bellingham, Washington and Pain MD Medical Associates in San Clemente, California.